Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aridis Pharmaceuticals (ARDS : NSDQ)

• Company Description    Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $1.07 Daily Weekly Monthly 20 Day Moving Average: 59,348 shares Shares Outstanding: 17.70 (millions) Market Capitalization: $18.94 (millions) Beta: 0.42 52 Week High: $7.72 52 Week Low: $0.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.74% -10.74% 12 Week -50.69% -45.80% Year To Date -54.08% -46.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 983 University Avenue Bldg. B - Los Gatos,CA 95032 USA ph: 408-385-1742 fax: 408-960-3822 dave@redchip.com http://www.aridispharma.com

• General Corporate Information    Officers Vu Truong - Chief Executive Officer; Chief Scientific Officer Eric Patzer - Executive Chairman and Director Fred Kurland - Chief Financial Officer and Principal Accounting O Robert R. Ruffolo - Director John Hamilton - Director Peer Information Aridis Pharmaceuticals (CORR.) Aridis Pharmaceuticals (RSPI) Aridis Pharmaceuticals (CGXP) Aridis Pharmaceuticals (BGEN) Aridis Pharmaceuticals (GTBP) Aridis Pharmaceuticals (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 040334104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 17.70 Most Recent Split Date: (:1) Beta: 0.42 Market Capitalization: $18.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 8.22 EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: 52.17% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 108.25% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -219.55 12/31/21 - -232.04 09/30/21 - -227.65 Current Ratio 03/31/22 - 0.64 12/31/21 - 0.73 09/30/21 - 0.82 Quick Ratio 03/31/22 - - 12/31/21 - 0.73 09/30/21 - 0.82 Operating Margin 03/31/22 - -2,097.53 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - -2,066.20 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -1,868.46 12/31/21 - -2,748.73 09/30/21 - -7,154.38 Book Value 03/31/22 - -1.15 12/31/21 - -0.93 09/30/21 - -0.34 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©